BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22130125)

  • 1. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Tews V; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
    Urol Oncol; 2013 Oct; 31(7):1148-54. PubMed ID: 22130125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer.
    Todenhöfer T; Hennenlotter J; Kühs U; Tews V; Gakis G; Aufderklamm S; Stenzl A; Schwentner C
    Urology; 2012 Mar; 79(3):620-4. PubMed ID: 22386412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
    Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
    Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
    Miyoshi Y; Matsuzaki J; Miura T
    Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
    Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
    Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
    Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
    Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
    Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
    Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
    Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract].
    Shao Y; Zhuang J; Xu SX; Liu DY
    Ai Zheng; 2002 Sep; 21(9):1005-7. PubMed ID: 12508552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
    Bier S; Hennenlotter J; Esser M; Mohrhardt S; Rausch S; Schwentner C; Maas M; Deininger S; Walz S; Bedke J; Stenzl A; Todenhöfer T
    Dis Markers; 2018; 2018():5823870. PubMed ID: 29651327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
    Kehinde EO; Al-Mulla F; Kapila K; Anim JT
    Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology.
    Huang WT; Li LY; Pang J; Ruan XX; Sun QP; Yang WJ; Gao X
    Neoplasma; 2012; 59(4):355-60. PubMed ID: 22489689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urinary tumor marker for urothelial cancer].
    Ohtani M; Iwasaki A; Shiraiwa H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
    Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
    Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.